Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 36, Issue 4, 2003, Pages 303-309

  Zlatanic, Jusuf ^a   Korelitz, Burton I ^a,b   Rajapakse, Ramona ^a   Kim, Peter S ^a   Rubin, Steven D ^a   Baiocco, Peter J ^a   Panagopoulos, Georgia ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LENOX HILL HOSPITAL   (United States)

Author keywords

6 Mercaptopurine; Child development; Complications; Inflammatory bowel disease; Pregnancy

Indexed keywords

MERCAPTOPURINE;

ADULT; AMNIOCENTESIS; ARTICLE; BIRTH WEIGHT; CHILD DEVELOPMENT; CLINICAL FEATURE; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROHN DISEASE; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ABORTION, SPONTANEOUS; ADULT; CASE-CONTROL STUDIES; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FETAL DEATH; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFLAMMATORY BOWEL DISEASES; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREVALENCE; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT;

EID: 0037376898     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200304000-00005     Document Type: Article

References (50)

1. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
2. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985;30:58-64.
3. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101:39-46.
4. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-51.
5. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-22.
6. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-4.
7. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gostroenterol 1993;88: 1198-205.
8. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
9. Korelitz BI, Fleisher MR, Sacknoff AL. Should toxicity to 6-MP serve to discourage long term maintenance therapy of IBD? Experience of the past quarter century. Am J Gastroenterol 1996;91:A665.
10. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-6.
11. Francella A, Dayan A, Rubin P, et al. 6-Mercaptopurine (6-MP) is safe therapy for child bearing patients with inflammatory bowel disease (IBD): a case controlled study. Gastroenterology 1996;110:A909.
12. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984;6:211-6.
13. Ventura SJ, Martin JA, Curtin SC, et al. Births: final data for 1997. Natl Vital Statist Rep 1999;47:1-93.
14. Rosenkrantz JG, Githens JH, Cox SM, et al. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967;97:387-94.
15. Grubb RB, Montiegel EC. The teratogenic effects of 6-mercaptopurine on chick embryos in ovo. Teratology 1975;11:179-85.
16. Reimers TJ, Sluss PM. 6-Mercaptopurine treatment of pregnant mice: effects on second and third generation. Science 1978;201:65-7.
17. Shah RM, Burdett DN. Developmental abnormalities induced by 6-mercaptopurine in the hamster. Can J Physiol Pharmacol 1979;57:53-8.
18. Schmid BP. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate or cyclosporin A. Toxicology 1984;31:9-21.
19. Amemiya K, Keen CL, Hurley LS. 6-Mercaptopurine induced alterations in mineral metabolism and teratogenesis in the rat. Teratology 1986;34:321-34.
20. Burdett DN, Shah RM. Gross and cellular analysis of 6-mercaptopurine-induced cleft palate in hamster. Am J Anat 1988;181:179-94.
21. Hou S. Pregnancy in women with chronic renal disease. N Engl J Med 1985;312:836-9.
22. Cararach V, Carmona F, Monleon FJ, et al. Pregnancy after renal transplantation: 25 years experience in Spain. Br J Obstet Gynaecol 1993;100:122-5.
23. Registration Committee of the European Dialysis and Transplant Association. Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol 1980;87:830-45.
24. Harding K, Freeman J. Weston W, et al. Trisomy 22: prenatal diagnosis - a case report. Ultrasound Obstet Gynecol 1995;5:136-7.
25. Boue A, Boue J, Gropp A. Cytogenetics of pregnancy wastage. Annu Rev Genet 1985;14:1-57.
26. Prasher VP, Roberts E, Norman A, et al. Partial trisomy 22 (q11.2-q13.1) as a result of duplication and pericentric inversion. J Med Genet 1995;32:306-8.
27. Pater JMD, Schuring-Blom GH, Van Den Bogaard R, et al. Maternal uniparental disomy for chromosome 22 in a child with generalized mosaicism for trisomy 22. Prenat Diagn 1997;17:81-6.
28. Robinson WP, Binkert F, Bernasconi F, et al. Molecular studies of chromosomal mosaicism: relative frequency of chromosome gain or loss and possible role of cell selection. Am J Hum Genet 1995;56:444-51.
29. Hsu LY, Yu MT, Neu RL, et al. Rare trisomy mosaicism diagnosed in amniocytes, involving an autosome other than chromosomes 13, 18, 20 and 21: karyotype/phenotype correlations. Prenat Diagn 1997;17:3:201-42.
30. Price HV, Salaman JR, Laurence KM, et al. Immunosuppressive drugs and the fetus. Transplantation 1976;21:294-8.
31. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319:189-94.
32. Simpson JL, Carson SA. Genetic and non-genetic causes of spontaneous abortions. In: Sciarra JJ, ed. Gynecology and Obstetrics, vol. 3. Philadelphia: Lippincott, 1995.
33. De Dombal FT, Watts JM, Watkinson G, et al. Ulcerative colitis and pregnancy. Lancet 1965;2:599-602.
34. Levy N, Roisman I, Teodor I. Ulcerative colitis in pregnancy in Israel. Dis Colon Rectum 1981;24:351-4.
35. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980;21: 469-74.
36. McEwan HP. Anorectal conditions in obstetric practice. Proc R Soc Med 1972; 65:279-81.
37. Mogadam M, Dobbins WO, Korelitz BI. et al. Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome. Gostroenterology 1981;80:72-6.
38. Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983;18:735-42.
39. Schade RR, Van Thiel DH, Gavaler JS. Chronic idiopathic ulcerative colitis: pregnancy and fetal outcome. Dig Dis Sci 1984;29:614-19.
40. De Dombal FT, Burton IL, Goligher JC. Crohn's disease and pregnancy. Br Med J 1972;3:550-3.
41. Fielding JF, Cooke WT. Pregnancy and Crohn's disease. Br Med J 1970;2:76-7.
42. Crohn BB, Yarnis H, Korelitz BI. Regional ileitis complicating pregnancy. Gastroenterology 1956;31:615-24.
43. Porter RJ, Stirrat GM. The effects of inflammatory bowel disease on pregnancy: a case-controlled retrospective analysis. Br J Obstet Gynaecol 1986;93:1124-31.
44. Jarnerot G. Fertility, sterility, and pregnancy in chronic inflammatory bowel disease. Scand J Gastroenterol 1982;17:1-4.
45. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989;160:998-1001.
46. Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984;19:724-32.
47. Korelitz BI. Epidemiological and psychosocial aspects of inflammatory bowel disease with observations on children, families, and pregnancy. Am J Gastroenterol 1982;77:929-33.
48. Kalousek DK, Pantzar T, Tsai M, et al. Early spontaneous abortion: morphologic and karyotypic findings in 3,912 cases. Birth Defects (Original Articles Series) 1993;29:53-61.
49. Hook EB. Rates of chromosomal abnormalities at different maternal ages. Obstet Gynaecol 1981;58:282-5.
50. Rajapakse R, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers with inflammatory bowel disease are treated with 6-mercaptopurine. Am J Gastroenterol 2000;95:684-8.